Adil Daud

48.3k total citations · 7 hit papers
315 papers, 16.1k citations indexed

About

Adil Daud is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Adil Daud has authored 315 papers receiving a total of 16.1k indexed citations (citations by other indexed papers that have themselves been cited), including 213 papers in Oncology, 157 papers in Molecular Biology and 77 papers in Immunology. Recurrent topics in Adil Daud's work include Cancer Immunotherapy and Biomarkers (111 papers), Melanoma and MAPK Pathways (96 papers) and CAR-T cell therapy research (87 papers). Adil Daud is often cited by papers focused on Cancer Immunotherapy and Biomarkers (111 papers), Melanoma and MAPK Pathways (96 papers) and CAR-T cell therapy research (87 papers). Adil Daud collaborates with scholars based in United States, Australia and France. Adil Daud's co-authors include Omid Hamid, Pamela N. Münster, Antoni Ribas, Caroline Robert, Daniel M. Sullivan, Alain P. Algazi, Katy K. Tsai, Nageatte Ibrahim, Douglas C. Marchion and Jeffrey S. Weber and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Adil Daud

297 papers receiving 15.8k citations

Hit Papers

Pembrolizumab versus ipilimumab for advance... 2008 2026 2014 2020 2017 2014 2019 2019 2008 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
    2017 898 citations Jacob Schachter, Antoni Ribas et al. profile →
  2. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
    2014 889 citations Michael D. Rosenblum, Adil Daud et al. profile →
  3. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
    2019 768 citations Caroline Robert, Antoni Ribas et al. profile →
  4. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    2019 638 citations Omid Hamid, Caroline Robert et al. profile →
  5. Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma
    2008 503 citations Adil Daud, Ronald C. DeConti et al. Journal of Clinical Oncology profile →
  6. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
    2019 443 citations Adil Daud et al. profile →
  7. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
    2015 382 citations Omid Hamid, Wells A. Messersmith et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adil Daud United States 63 10.3k 7.4k 5.2k 1.7k 1.2k 315 16.1k
Patrick Hwu United States 53 10.8k 1.0× 6.6k 0.9× 7.7k 1.5× 2.4k 1.4× 1.7k 1.3× 200 17.4k
Ulrich Keilholz Germany 65 9.2k 0.9× 6.1k 0.8× 5.8k 1.1× 2.2k 1.3× 1.8k 1.4× 477 15.5k
Louis M. Weiner United States 65 8.5k 0.8× 6.6k 0.9× 5.3k 1.0× 2.3k 1.3× 1.8k 1.4× 256 16.6k
Keith L. Knutson United States 55 6.4k 0.6× 4.7k 0.6× 6.7k 1.3× 1.4k 0.8× 1.7k 1.4× 187 14.3k
Igor Puzanov United States 59 10.2k 1.0× 6.8k 0.9× 3.9k 0.7× 3.2k 1.8× 1.8k 1.4× 302 15.5k
Jason J. Luke United States 48 8.2k 0.8× 4.7k 0.6× 4.9k 0.9× 2.1k 1.2× 1.5k 1.2× 296 13.2k
Mary L. Disis United States 60 7.8k 0.8× 4.4k 0.6× 8.5k 1.6× 1.3k 0.7× 1.1k 0.9× 278 14.0k
Gavin P. Dunn United States 45 8.4k 0.8× 4.2k 0.6× 8.9k 1.7× 1.8k 1.1× 1.9k 1.6× 136 16.4k
José R. Conejo-García United States 58 5.8k 0.6× 5.3k 0.7× 7.2k 1.4× 945 0.6× 1.7k 1.4× 208 14.2k
Kongming Wu China 68 7.6k 0.7× 8.0k 1.1× 4.2k 0.8× 2.5k 1.5× 3.3k 2.6× 187 16.5k

Countries citing papers authored by Adil Daud

Since Specialization
Citations

This map shows the geographic impact of Adil Daud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adil Daud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adil Daud more than expected).

Fields of papers citing papers by Adil Daud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adil Daud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adil Daud. The network helps show where Adil Daud may publish in the future.

Co-authorship network of co-authors of Adil Daud

This figure shows the co-authorship network connecting the top 25 collaborators of Adil Daud. A scholar is included among the top collaborators of Adil Daud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adil Daud. Adil Daud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mahuron, Kelly M., Laura A. Huppert, Margaret M. Lowe, et al.. (2025). Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma. Cancer Research. 85(8). 1424–1440. 2 indexed citations
2.
Wong, Paul, Andrew D. Wisneski, Katy K. Tsai, et al.. (2024). Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors. World Journal of Surgical Oncology. 22(1). 77–77. 2 indexed citations
3.
Haugh, Alexandra M., Robert C. Osorio, R François, et al.. (2024). Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations. Cancers. 16(7). 1347–1347. 1 indexed citations
4.
Henry, Jason T., Janice M. Mehnert, Erika Rudnicki, Juan Pinelli, & Adil Daud. (2023). Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).. Journal of Clinical Oncology. 41(16_suppl). TPS9597–TPS9597. 1 indexed citations
5.
Robert, Caroline, Matteo S. Carlino, Catriona M. McNeil, et al.. (2023). Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology. 41(24). 3998–4003. 63 indexed citations
6.
7.
Ribas, Antoni, Adil Daud, Anna C. Pavlick, et al.. (2019). Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma. Clinical Cancer Research. 26(1). 46–53. 30 indexed citations
8.
Algazi, Alain P., Katy K. Tsai, Lawrence R. Chen, et al.. (2019). Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunology Research. 8(2). 246–254. 68 indexed citations
9.
Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations
10.
Algazi, Alain P., Katy K. Tsai, Alexander N. Shoushtari, et al.. (2016). Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies. Cancer. 122(21). 3344–3353. 265 indexed citations
11.
Daud, Adil, et al.. (2015). STUDI SANITASI RUMAH SAKIT IBNU SINA MAKASSAR DAN RUMAH SAKIT PELAMONIA MAKASSAR. Hasanuddin University Repository.
12.
Daud, Adil, et al.. (2014). ANALISIS RISIKO ARSEN (As) DALAM IKAN KEMBUNG DAN KERANG DARAH DI WILAYAH PESISIR MAKASSAR. Hasanuddin University Repository. 2 indexed citations
13.
Daud, Adil. (2013). PERBEDAAN MALARIA PADA DAERAH DATARAN RENDAH DENGAN DATARAN TINGGI DI KABUPATEN MALUKU TENGGARA BARAT. Hasanuddin University Repository. 1 indexed citations
14.
Daud, Adil, et al.. (2013). IDENTIFIKASI RESIDU PESTISIDA GOLONGAN ORGANOKLORIN BAHAN AKTIF LINDAN PADA WORTEL DI PASAR TRADISIONAL (PASAR TERONG) DAN PASAR MODEREN (SWALAYAN RAMAYANA M???TOS) KOTA MAKASSAR TAHUN 2013. Hasanuddin University Repository. 2 indexed citations
15.
Daud, Adil, et al.. (2012). In vitro evaluation of Moringa oleifera gum for colon- specific drug delivery. International Journal of Pharmaceutical Investigation. 2(1). 48–48. 21 indexed citations
16.
Daud, Adil, Smitha Krishnamurthi, Mansoor N. Saleh, et al.. (2011). Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(4). 1092–1100. 68 indexed citations
17.
Daud, Adil, Jana L. Dawson, Ronald C. DeConti, et al.. (2009). Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Clinical Cancer Research. 15(7). 2479–2487. 78 indexed citations
18.
Daud, Adil, Ronald C. DeConti, Stephanie Andrews, et al.. (2008). Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 26(36). 5896–5903. 503 indexed citations breakdown →
19.
Solit, David B., Iman Osman, David Polsky, et al.. (2008). Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. Clinical Cancer Research. 14(24). 8302–8307. 146 indexed citations
20.
Simon, George R., Christopher R. Garrett, Stephen C. Olson, et al.. (2006). Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study. Clinical Cancer Research. 12(15). 4645–4651. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Hwu Breakdown of academic impact, for papers by Ulrich Keilholz Breakdown of academic impact, for papers by Louis M. Weiner Breakdown of academic impact, for papers by Keith L. Knutson Breakdown of academic impact, for papers by Igor Puzanov Breakdown of academic impact, for papers by Jason J. Luke Breakdown of academic impact, for papers by Mary L. Disis Breakdown of academic impact, for papers by Gavin P. Dunn Breakdown of academic impact, for papers by José R. Conejo-García Breakdown of academic impact, for papers by Kongming Wu
Rankless by CCL
2026